课题基金 / 基金详情

GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES

GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES
对降脂药物引起的肌病的遗传易感性
批准号：
8174438
负责人：
MICHAEL H. WEISMAN
金额：
$1.66万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-12-01 至 2010-11-30
来源：
https://reporter.nih.gov/project-details/8174438
关键词：
Computer Retrieval of Information on Scientific Projects DatabaseFundingGene MutationGenetic Predisposition to DiseaseGrantHigh PrevalenceHydroxymethylglutaryl-CoA Reductase InhibitorsIndividualInstitutionLipidsMetabolicMyopathyPatientsPharmaceutical PreparationsRecruitment ActivityResearchResearch PersonnelResourcesSourceUnited States National Institutes of Health

项目摘要

项目成果

MICHAEL H. WEISMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine if individuals who are treated with HMG-CoA reductase inhibitors and develop myopathy have a higher prevalence of genetic mutations causing metabolic muscle diseases. Two-hundred patients will be recruited into the study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RHEUMATOID ARTHRITIS ASSOCIATED AUTOIMMUNITY IN HIGH RISK POPULATIONS
A COMPREHENSIVE MODEL OF SEVERITY IN OUTCOMES IN ANKYLOSING SPONDYLITIS
INFLAMMATORY MARKERS IN THE STOOL AND SERUM OF PATIENTS WITH ANKYLOSING SPONDYLI
PROJECT 3: DEFINING THE SPECTRUM OF SPONDYLOARTHRITIS IN FAMILY MEMBERS
海外基金